HPS-115 - Real-World venetoclax dosage in patients with Acute Myeloid Leukemia receiving moderate or strong CYP3A4 inhibitors

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-115
• By: HANAWA, Juri (Kameda Medical Center, Japan)
• Co-author(s): Ms Juri Hanawa (Kameda Medical Center, Kamogawa, Japan)
  Mr Masanori Suzuki (Teikyo Heisei University, Nakano, Japan)
  Mr Satoshi Yuyama (Kameda Medical Center, Kamogawa, Japan)
  Mr Tatsuya Isezaki (Kameda Medical Center, Kamogawa, Japan)
  Mr Ryohkan Funakoshi (Kameda Medical Center, Kamogawa, Japan)
  
• Abstract:

  Introduction
  Regimens containing venetoclax (VEN) are becoming the standard treatment for patients with acute myeloid leukemia (AML) who are ineligible for intensified chemotherapy. However, VEN is primarily metabolized by CYP3A4, necessitating careful consideration of potential drug interactions. When moderate or strong CYP3A4 inhibitors are..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login